GEA
ALNY icon

Glen Eagle Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Glen Eagle Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$301 Hold
1
– – ﹤0.01% 1053
2026
Q1 		$331 Hold
1
– – ﹤0.01% 985
2025
Q4 		$398 Buy
+1
New +$443 ﹤0.01% 1012
2017
Q3 		– Sell
-110
Closed -$8.77K – 633
2017
Q2 		$8.77K Sell
110
-110
-50% -$7.03K 0.01% 410
2017
Q1 		$11.3K Buy
+220
New +$10.2K 0.01% 352

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Glen Eagle Advisors's ALNY Position: Q2 2026 in Review

Glen Eagle Advisors held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 1 share worth $301. The position accounts for ﹤0.01% of the portfolio, ranked #1053.

Glen Eagle Advisors first reported a position in ALNY in Q1 2017 and has held it in 5 quarters since. The position peaked at $11.3K in Q1 2017. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Glen Eagle Advisors held 1 share of Alnylam Pharmaceuticals worth $301 as of Q2 2026.
  • Glen Eagle Advisors left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Glen Eagle Advisors's portfolio in Q2 2026, its #1053 holding.
  • Glen Eagle Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2017 and has held it in 5 quarters since.
  • Glen Eagle Advisors's Alnylam Pharmaceuticals position peaked at $11.3K in Q1 2017.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Glen Eagle Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.